HC Wainwright Issues Negative Forecast for Immunome Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for Immunome in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($2.64) for the year, down from their previous forecast of ($2.45). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome’s Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at ($2.41) EPS, FY2029 earnings at ($1.63) EPS and FY2030 earnings at ($0.42) EPS.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.14).

IMNM has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Stifel Nicolaus decreased their price target on Immunome from $24.00 to $23.00 and set a “hold” rating on the stock in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Immunome in a research report on Tuesday, October 27th. Truist Financial boosted their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Piper Sandler reduced their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.85.

Immunome Price Performance

Shares of Immunome stock opened at $19.07 on Thursday. The business has a 50 day simple moving average of $20.99 and a two-hundred day simple moving average of $22.30. Immunome has a 12 month low of $16.11 and a 12 month high of $30.06. The stock has a market capitalization of $2.17 billion, a P/E ratio of -7.22 and a beta of 2.68.

Hedge Funds Weigh In On Immunome

A number of large investors have recently bought and sold shares of IMNM. BlackRock Inc. acquired a new position in Immunome during the 2nd quarter worth approximately $186,588,000. Primecap Management Co. CA purchased a new stake in shares of Immunome during the 2nd quarter worth approximately $97,081,000. Bank of America Corp DE purchased a new stake in shares of Immunome during the 2nd quarter worth approximately $13,729,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Immunome in the 2nd quarter worth approximately $12,591,000. Finally, Wellington Management Group LLP grew its holdings in shares of Immunome by 10.1% in the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock worth $110,404,000 after acquiring an additional 478,239 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company’s stock.

More Immunome News

These are some of the IMNM news items that stood out recently:

• Neutral Sentiment: Price targets were trimmed but remain above the $19.07 reference price: Piper Sandler cut its target from $33 to $30 and kept an Overweight rating; Stifel Nicolaus lowered its target from $24 to $23 and maintained Hold. The cuts are cautious, while the ratings and targets indicate potential upside. Piper Sandler target article Stifel Nicolaus article
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to a loss of $0.76 per share from a loss of $0.68, and cut its FY2026 estimate to a loss of $2.64 from $2.45. It also lowered estimates for FY2027–FY2030, including changing its FY2029 forecast from $0.40 profit to a $1.63 loss and its FY2030 forecast from $1.08 profit to a $0.42 loss. These revisions point to a longer path to profitability and could weigh on investor sentiment.

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.